Quantitative Bias Analysis of Drug-induced phenoconversion and signal dilution in breast cancer Pharmacogenetics

BACKGROUND AND OBJECTIVE: The clinical utility of CYP2D6 genotyping in tamoxifen therapy remains controversial because most large studies produced inconsistent results without accounting for inhibitory co-medications, which functionally convert genetic normal metabolizers into poor metabolizers (PM). This "phenoconversion gap" represents a critical drug-drug-gene interaction (DDGI) that is hypothesized to introduce a systematic pharmacokinetic signal dilution in survival estimates. We aimed to quantify the impact of drug-induced phenoconversion on the predictive utility of CYP2D6 through a systematic audit and quantitative bias analysis (QBA). METHODS: We audited 33 primary studies, identified from the most comprehensive meta-analysis of tamoxifen pharmacogenetics conducted to date, and developed a Monte Carlo simulation model (5000 iterations) to "purify" genetic normal metabolizer reference arms. Patients were stochastically reassigned to functional phenotypes across inhibitor prevalence scenarios (0-35%). The model was internally validated against clinical cohorts exclusively receiving tamoxifen (monotherapy subgroups) using a random-effects framework with error propagation. RESULTS: The audit revealed that 100% of studies published since 2015 (n = 11, following international consensus guidelines) failed to adopt phenotype reclassification, although 4 earlier cohorts (12.1% overall) had implemented inhibitor adjustments. QBA demonstrated a linear dose-response restoration of the pharmacokinetic signal, revealing that genetically-mediated bioactivation deficiency is significantly underestimated when the DDGI component is omitted. At 35% prevalence, the median purified relative risk (RR) for recurrence rose to 1.58 (95% simulation interval 1.36-1.84), representing a 36.7% increase compared to the unadjusted baseline. At a clinically plausible 20% prevalence, the pooled RR for recurrence increased from 1.42 [95% confidence interval (CI) 1.14-1.76] to 1.51 (95% CI 1.16-1.97) for intermediate metabolizers (IM), and from 1.58 (95% CI 1.19-2.09) to 1.92 (95% CI 1.28-2.88) for PM. Mortality estimates showed a negligible shift for IM (1.15-1.14) and a modest trend for PM (RR: 1.61-1.81; 95% CI 0.79-4.15). Risk estimate restoration was consistent across ethnic strata. While the model achieved a predictive coverage of 47.1% in validation, the broadened CIs limited the impact on overall statistical significance. CONCLUSION: The "Phenoconversion Gap" represents a systematic source of pharmacokinetic signal dilution that directionally masks the impact of CYP2D6-mediated bioactivation on recurrence. While correcting for this DDGI aligns clinical estimates with pharmacological principles, it does not fundamentally alter the stability of current meta-analytic conclusions at common prevalence thresholds. This suggests that the observed inconsistencies in tamoxifen pharmacogenetics stem from a complex interplay of co-existing biases beyond drug-induced enzymatic inhibition alone.